Low-dose aspirin (acetylsalicylate) prevents increases in brain PGE2, 15-epi-lipoxin A4 and 8-isoprostane concentrations in 9 month-old HIV-1 transgenic rats, a model for HIV-1 associated neurocognitive disorders

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 96, Issue , 2015, Pages 25-30

  Blanchard, Helene C ^a   Taha, Ameer Y ^a   Rapoport, Stanley I ^a   Yuan, Zhi Xin ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

8 Isoprostane; Brain; Chronic aspirin; HIV 1; PGE2; Rat

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 5 EPI LIPOXIN A4; 8 ISOPROSTANE; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; ICOSANOID; LEUKOTRIENE B4; LIPOXIN A; OMEGA 3 FATTY ACID; PROSTAGLANDIN E2; RESOLVIN D1; THROMBOXANE B2; UNCLASSIFIED DRUG; 15-METHYL-LIPOXIN A4; 8-EPI-PROSTAGLANDIN F2ALPHA; LIPOXIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN F2 ALPHA; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BEHAVIOR CHANGE; BIOACCUMULATION; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID ANALYSIS; LIPID BRAIN LEVEL; LIPID METABOLISM; LOW DRUG DOSE; MALE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; NEUROCOGNITIVE DISORDERS; TRANSGENIC RAT;

HUMAN IMMUNODEFICIENCY VIRUS 1; RATTUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BRAIN; DINOPROST; DINOPROSTONE; DISEASE MODELS, ANIMAL; HIV-1; LIPOXINS; MALE; NEUROCOGNITIVE DISORDERS; RATS; RATS, TRANSGENIC; VASOCONSTRICTOR AGENTS;

EID: 84927108823     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2015.01.002     Document Type: Article

References (65)

1. Sacktor N., McDermott M.P., Marder K., Schifitto G., Selnes O.A., McArthur J.C., Stern Y., Albert S., Palumbo D., Kieburtz K., De Marcaida J.A., Cohen B., Epstein L. HIV-associated cognitive impairment before and after the advent of combination therapy. J. Neurovirol. 2002, 8:136-142.
2. Letendre S., Ellis R.J. Neurologic complications of HIV disease and their treatments. Top. HIV Med. 2006, 14:21-26.
3. Gonzalez-Scarano F., Martin-Garcia J. The neuropathogenesis of AIDS. Nat. Rev. Immunol. 2005, 5:69-81.
4. Ghafouri M., Amini S., Khalili K., Sawaya B.E. HIV-1 associated dementia: symptoms and causes. Retrovirology 2006, 3:28.
5. Sevigny J.J., Albert S.M., McDermott M.P., McArthur J.C., Sacktor N., Conant K., Schifitto G., Selnes O.A., Stern Y., McClernon D.R., Palumbo D., Kieburtz K., Riggs G., Cohen B., Epstein L.G., Marder K. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004, 63:2084-2090.
6. Dhasmana D.J., Dheda K., Ravn P., Wilkinson R.J., Meintjes G. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 2008, 68:191-208.
7. Heyes M.P., Ellis R.J., Ryan L., Childers M.E., Grant I., Wolfson T., Archibald S., Jernigan T.L. Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection. Brain: A Journal of Neurology 2001, 124:1033-1042.
8. Kamat A., Lyons J.L., Misra V., Uno H., Morgello S., Singer E.J., Gabuzda D. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J. Acquir. Immune Defic. Syndr. 2012, 60:234-243.
9. Muller W.E., Pergande G., Ushijima H., Schleger C., Kelve M., Perovic S. Neurotoxicity in rat cortical cells caused by N-methyl-d-aspartate (NMDA) and gp120 of HIV-1: induction and pharmacological intervention. Prog. Mol. Subcell Biol. 1996, 16:44-57.
10. Serhan C.N. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity?. Prostaglandins 1997, 53:107-137.
11. Bray M.A., Cunningham F.M., Ford-Hutchinson A.W., Smith M.J. Leukotriene B4: a mediator of vascular permeability. Br. J. Pharmacol. 1981, 72:483-486.
12. Claria J., Serhan C.N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:9475-9479.
13. Serhan C.N. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediators 2002, 68-69:433-455.
14. Hernandez M., Bayon Y., Sanchez Crespo M., Nieto M.L. Signaling mechanisms involved in the activation of arachidonic acid metabolism in human astrocytoma cells by tumor necrosis factor-alpha: phosphorylation of cytosolic phospholipase A2 and transactivation of cyclooxygenase-2. J. Neurochem. 1999, 73:1641-1649.
15. Mollace V., Colasanti M., Rodino P., Lauro G.M., Nistico G. HIV coating gp 120 glycoprotein-dependent prostaglandin E2 release by human cultured astrocytoma cells is regulated by nitric oxide formation. Biochem. Biophys. Res. Commun. 1994, 203:87-92.
16. Flora G., Pu H., Hennig B., Toborek M. Cyclooxygenase-2 is involved in HIV-1 Tat-induced inflammatory responses in the brain. Neuromolecular Med. 2006, 8:337-352.
17. Maccarrone M., Bari M., Corasaniti M.T., Nistico R., Bagetta G., Finazzi-Agro A. HIV-1 coat glycoprotein gp120 induces apoptosis in rat brain neocortex by deranging the arachidonate cascade in favor of prostanoids. J. Neurochem. 2000, 75:196-203.
18. Bagetta G., Corasaniti M.T., Paoletti A.M., Berliocchi L., Nistico R., Giammarioli A.M., Malorni W., Finazzi-Agro A. HIV-1 gp120-induced apoptosis in the rat neocortex involves enhanced expression of cyclo-oxygenase type 2 (COX-2). Biochem. Biophys. Res. Commun. 1998, 244:819-824.
19. Rao J.S., Kim H.W., Kellom M., Greenstein D., Chen M., Kraft A.D., Harry G.J., Rapoport S.I., Basselin M. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in brain of HIV-1 transgenic rats. J. Neuroinflammation 2011, 8:101.
20. Pereira C.F., Boven L.A., Middel J., Verhoef J., Nottet H.S. Induction of cyclooxygenase-2 expression during HIV-1-infected monocyte-derived macrophage and human brain microvascular endothelial cell interactions. J. Leukocyte Biol. 2000, 68:423-428.
21. Moses G.S., Jensen M.D., Lue L.F., Walker D.G., Sun A.Y., Simonyi A., Sun G.Y. Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease. J. Neuroinflammation 2006, 3:28.
22. Lee J.C., Simonyi A., Sun A.Y., Sun G.Y. Phospholipases A2 and neural membrane dynamics: implications for Alzheimer's disease. J. Neurochem. 2011, 116:813-819.
23. Chaudhry U., Zhuang H., Dore S. Microsomal prostaglandin E synthase-2: cellular distribution and expression in Alzheimer's disease. Exp. Neurol. 2010, 223:359-365.
24. Bhattacharyya D.K., Lecomte M., Dunn J., Morgans D.J., Smith W.L. Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. Arch. Biochem. Biophys. 1995, 317:19-24.
25. Lecomte M., Laneuville O., Ji C., DeWitt D.L., Smith W.L. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J. Biol. Chem. 1994, 269:13207-13215.
26. Serhan C.N., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G., Moussignac R.L. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 2002, 196:1025-1037.
27. Senol N., Ceyhan B.M., Ersoy I.H., Senol A., Acarturk G., Sutcu R. Aspirin increases NMDA receptor subunit 2A concentrations in rat hippocampus. J. Recept Signal Transduction Res. 2012, 32:17-21.
28. Maharaj H., Maharaj D.S., Saravanan K.S., Mohanakumar K.P., Daya S. Aspirin curtails the acetaminophen-induced rise in brain norepinephrine levels. Metab. Brain Dis. 2004, 19:71-77.
29. Kurata K., Nishida N., Tsukuda R., Suzuki T., Sato S., Tokuriki M. Frequency selectivity on aspirin-induced hearing loss in rats with auditory stimulus-induced conditioned suppression. J. Vet. Med. Sci. 1997, 59:879-884.
30. Stolk P., Souverein P.C., Wilting I., Leufkens H.G., Klein D.F., Rapoport S.I., Heerdink E.R. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fatty Acids 2010, 82:9-14.
31. Laan W., Grobbee D.E., Selten J.P., Heijnen C.J., Kahn R.S., Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2010, 71:520-527.
32. Ketterer M.W., Brymer J., Rhoads K., Kraft P., Lovallo W.R. Is aspirin, as used for antithrombosis, an emotion-modulating agent?. J. Psychosom. Res. 1996, 40:53-58.
33. Reid W., Sadowska M., Denaro F., Rao S., Foulke J., Hayes N., Jones O., Doodnauth D., Davis H., Sill A., O'Driscoll P., Huso D., Fouts T., Lewis G., Hill M., Kamin-Lewis R., Wei C., Ray P., Gallo R.C., Reitz M., Bryant J. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:9271-9276.
34. Lashomb A.L., Vigorito M., Chang S.L. Further characterization of the spatial learning deficit in the human immunodeficiency virus-1 transgenic rat. J. Neurovirol. 2009, 15:14-24.
35. Taha A.Y., Basselin M., Ramadan E., Modi H.R., Rapoport S.I., Cheon Y. Altered lipid concentrations of liver, heart and plasma but not brain in HIV-1 transgenic rats. Prostaglandins Leukot Essent Fatty Acids 2012, 87:91-101.
36. Voisin E.M., Ruthsatz M., Collins J.M., Hoyle P.C. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development. Regul. Toxicol. Pharm.-RTP 1990, 12:107-116.
37. Casado-Arroyo R., Gargallo C., Lanas Arbeloa A. Balancing the risk and benefits of low-dose aspirin in clinical practice. Best Pract. Res. Clin. Gastroenterol. 2012, 26:173-184.
38. Patrono C. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?. Eur. Heart J. 2013, 34:3403-3411.
39. Radin N.S. Extraction of tissue lipids with a solvent of low toxicity. Methods Enzymol. 1981, 72:5-7.
40. Aid S., Bosetti F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications. Biochimie 2011, 93:46-51.
41. Parepally J.M., Mandula H., Smith Q.R. Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin. Pharm. Res. 2006, 23:873-881.
42. Ajmone-Cat A.M., Bernado A., Greco A., Minghetti L. Non-steroidal antiinflammatory drugs and brain inflammation: effects on microglial functiona. Pharmaceuticals 2010, 6:1949-1965.
43. Patrignani P., Filabozzi P., Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 1982, 69:1366-1372.
44. Tohgi H., Konno S., Tamura K., Kimura B., Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke; A Journal of Cerebral Circulation 1992, 23:1400-1403.
45. Miyamoto T., Lindgren J.A., Hokfelt T., Samuelsson B. Regional distribution of leukotriene and mono-hydroxyeicosatetraenoic acid production in the rat brain. Highest leukotriene C4 formation in the hypothalamus. FEBS Lett. 1987, 216:123-127.
46. Lovelady G.K., Mirro R., Armstead W.M., Busija D.W., Leffler C.W. Effect of 15-HETE on cerebral arterioles of newborn pigs. Prostaglandins 1988, 36:507-513.
47. P. Rauch, A. Zellmer, C. Specht, D. Sperling, Interference in Immunoassays. Recognize and Avoid (Translation from German, ), Labowelt, 6 (2005), pp. 1-7. http://www.oxfordbiosystems.com/Portals/0/PDF_2/lw-IV-05-englisch.pdf.
48. Chiang N., Arita M., Serhan C.N. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids 2005, 73:163-177.
49. Wu Y., Ye X.H., Guo P.P., Xu S.P., Wang J., Yuan S.Y., Yao S.L., Shang Y. Neuroprotective effect of lipoxin A4 methyl ester in a rat model of permanent focal cerebral ischemia. J. Mol. Neurosci.: MN 2010, 42:226-234.
50. Genis P., Jett M., Bernton E.W., Boyle T., Gelbard H.A., Dzenko K., Keane R.W., Resnick L., Mizrachi Y., Volsky D.J., et al. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J. Exp. Med. 1992, 176:1703-1718.
51. Hallstrand T.S., Henderson W.R. An update on the role of leukotrienes in asthma. Curr. Opin. Allergy Clin. Immunol. 2010, 10:60-66.
52. Mathis S., Jala V.R., Haribabu B. Role of leukotriene B4 receptors in rheumatoid arthritis. Autoimmunity Rev. 2007, 7:12-17.
53. Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., Roberts L.J. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:9383-9387.
54. Montuschi P., Barnes P.J., Roberts L.J. Isoprostanes: markers and mediators of oxidative stress. FASEB J.: Official Publication of the Federation of American Societies for Experimental Biology 2004, 18:1791-1800.
55. Turchan J., Pocernich C.B., Gairola C., Chauhan A., Schifitto G., Butterfield D.A., Buch S., Narayan O., Sinai A., Geiger J., Berger J.R., Elford H., Nath A. Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology 2003, 60:307-314.
56. Uzasci L., Nath A., Cotter R. Oxidative stress and the HIV-infected brain proteome. J. Neuroimmune Pharmacol.: The Official Journal of the Society on NeuroImmune Pharmacology 2013, 8:1167-1180.
57. Nicolini A., Ajmone-Cat M.A., Bernardo A., Levi G., Minghetti L. Human immunodeficiency virus type-1 Tat protein induces nuclear factor (NF)-kappaB activation and oxidative stress in microglial cultures by independent mechanisms. J. Neurochem. 2001, 79:713-716.
58. Montine T.J., Montine K.S., McMahan W., Markesbery W.R., Quinn J.F., Morrow J.D. F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal 2005, 7:269-275.
59. Hong S., Gronert K., Devchand P.R., Moussignac R.L., Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids Anti-inflammation, The Journal of Biological Chemistry 2003, 278:14677-14687.
60. Serhan C.N., Yacoubian S., Yang R. Anti-inflammatory and proresolving lipid mediators. Annu. Rev. Pathol. 2008, 3:279-312.
61. Tornero C., Ventura A., Mafe M. Aspirin is indicated for primary prevention of cardiovascular events in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 2010, 54:560.
62. InfecBurkholder G.A.J, Tamhane A.R., Salinas J.L., Mugavero M.J., Raper J.L., Westfall A.O., Saag M.S., Willig J.H. Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. Clin. Infect. Dis.: An Official Publication of the Infectious Diseases Society of America 2012, 55:1550-1557.
63. Johansson C.C., Bryn T., Aandahl E.M., Areklett M.A., Aukrust P., Tasken K., Froland S.S. Treatment with type-2 selective and non-selective cyclooxygenase inhibitors improves T-cell proliferation in HIV-infected patients on highly active antiretroviral therapy. AIDS 2004, 18:951-952.
64. Clemente M.I., Alvarez S., Serramia M.J., Turriziani O., Genebat M., Leal M., Fresno M., Munoz-Fernandez M.A. Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4. Antiviral Ther. 2009, 14:1101-1111.
65. Kvale D., Ormaasen V., Kran A.M., Johansson C.C., Aukrust P., Aandahl E.M., Froland S.S., Tasken K. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment. AIDS 2006, 20:813-820.